Researchers have created an obesity medication that simultaneously targets five metabolic areas, offering hope beyond current treatments.

Every significant advancement in the treatment of obesity has resulted from focusing on an additional biochemical mechanism. However, what happens if five paths are simultaneously targeted by researchers? A team from Munich made the decision to investigate.

The study team solved a long-standing issue with one of the additional elements by creating a single molecule that simultaneously engages five biological targets. It worked better than other comparative drugs in obese mice.

Five targets, one molecule

The project was headed by Professor Timo D. Müller, who oversees the Institute for Diabetes and Obesity at Helmholtz Munich. His team aimed to increase the effects of existing gut hormone medications without the need for an additional pill that would flood the body.

A hybrid medication was the outcome. GLP-1 and GIP, two well-known gut hormones that reduce hunger and stabilise blood sugar, are mimicked by half of the molecule. The most potent obesity injectable available today, tirzepatide, is already powered by the same combination.

Lanifibranor, a medication that targets cellular proteins that regulate metabolism, is the second component. These proteins increase the cell's capacity to burn fat and manage blood sugar once they are active.

Together, the chemical targets three switches inside some cells and two receptors on their exterior. Five cellular pathways are simultaneously activated by the chemical. According to Müller, the senior author, "our guiding question was: how can we enhance incretin activity without creating a second, systemically active source of side effects?"

Delivery of targeted cells

On its own, lanifibranor has a good effect on metabolism but acts throughout the bloodstream. In previous human trials, this bodywide distribution led to issues such fluid retention, anaemia, and slight weight gain. By chemically binding lanifibranor to the gut hormone portion of the molecule, the Munich researchers circumvented that.

That part attaches itself to cells in the pancreas, gut, and brain that are aware of these gut hormones, GLP-1 and GIP, which alert the brain when you're full and maintain blood sugar levels. The lanifibranor only enters the cells there.

The amount of lanifibranor required was drastically decreased by that targeted delivery. Unintentional side effects were lessened because the dose was around 6,898 times lower than what lanifibranor alone needs to influence liver function.

Comparing medications for obesity

The hybrid was administered for two weeks to mice who were fed a high-fat diet to simulate human obesity. Compared to animals receiving semaglutide, the active ingredient in Ozempic and Wegovy, they consumed less food, shed more body fat, and lost more weight.

Additionally, the hybrid performed better than tirzepatide's typical GLP-1/GIP combo. When lanifibranor was connected to the GLP-1/GIP half of the molecule, it became far more successful in causing weight loss than when it was used alone.

One head-to-head trial found that tirzepatide is already more potent than semaglutide in people. In this preclinical comparison, the Munich chemical performed better than both. According to Dr. Daniela Liskiewicz, co-first author and group leader at Helmholtz Munich, "the animals ate less and lost more weight than under a GLP-1/GIP co-agonist without cargo."

Improved reaction to insulin

Compared to the conventional GLP-1/GIP combo, the medication lowered fasting blood sugar. The hybrid molecule clearly outperformed the reference medication in a clamp test, in which physicians infuse glucose and gauge how quickly insulin clears it.

Even after adjusting for body weight, some of that growth persisted. To match hybrid-treated weights, they put a different group on the older medication under dietary restrictions. In terms of controlling blood sugar, the hybrid continued to do better.

This implies that the medication enhances insulin sensitivity independently of weight loss. The blood-sugar effect vanished when researchers suppressed PPARδ in the same animals, yet weight reduction persisted.

Additionally, the same combination reduced muscle and liver inflammation and reduced liver fat. Patients with type 2 diabetes and fatty liver disease, which frequently coexist, may benefit from both effects.

Reduced adverse effects

Mice on the hybrid did not exhibit the usual side effects of lanifibranor in people, such as fluid retention, anemia, and slight weight increase. Kidney, heart, liver, and muscle tissue samples did not exhibit any harm.

Compared to untreated obese controls, obese mice on the hybrid had superior cardiac function; their hearts pumped more blood each beat. The blood pressure did not change. The same dosage did not cause lean, healthy mice to lose weight, body fat, or hunger, nor did it cause their blood sugar levels to plummet. It seems that the chemical primarily acts on impacted tissues.

From rodents to people

Prior to this study, no single compound including GLP-1, GIP, and three PPAR switches had been tried in a living animal. The Munich team had earlier released a report that simultaneously addressed three goals. What is novel in this study is the addition of GIP and the third PPAR switch.

Doctors may eventually provide a single weekly injection that treats inflammation, fatty liver, insulin response, blood sugar, and hunger if the theory holds true in humans. Following therapy discontinuation, patients may have less metabolic recovery.

The drawback is well known: it will require years of further research to get this chemical into humans, and animal outcomes frequently deteriorate in human trials. Müller stated, "We see a principle with strong effects in the animal model; now the task is to optimize the approach for humans and move it towards the clinic." Clinical testing will require industry partners.